Organische Nitrate und Thrombozytenfunktion

Zusammenfassung

Organische Nitrate unterschiedlicher chemischer Struktur sowie Nitroprussidnatrium und Molsidomin (bzw. ihre biologisch aktiven Metaboliten) können die (primäre) Aggregation und Sekretion von Humanthrombozyten in vitro und ex vivo hemmen. Eine solche Wirkung wird für Molsidomin (SIN-1) und Nitroprussidnatrium in vitro in Konzentrationen beobachtet, die in der gleichen Größenordnung liegen wie die vasodilatierenden Effekte der Substanzen. Dagegen sind für eine direkte Antiplättchenwirkung organischer Nitrate (Glyzeryltrinitrat, Isosorbiddinitr at, Isosorbidmononitrate, Teopranitol) in vitro Konzentrationen erforderlich, die ca. 100- bis 1000fach höher sind als die Plasmaspiegel der Substanzen nach therapeutischer Dosierung bzw. die Konzentrationen, die isolierte Gefäßstreifen relaxieren. Als gemeinsamer Wirkungsmechanismus der direkten thrombozy-tenfunktionshemmenden und gefäßerweiternden Wirkung all dieser Substanzen kann heute eine Stickoxid-(NO)-vermittelte Stimulation der cGMP-Bildung angenommen werden, das aus organischen Nitraten als »Pro-drug« entsteht. Die Freisetzung von NO, eines »endothelial cell-derived relaxing factors« (EDRF) aus Nitroprussidnatrium und SIN-1 erfolgt spontan. Dagegen erfordert die Freisetzung von NO aus organischen Nitraten einen enzymatischen Stoffwechselweg, der in isolierten Thrombozyten nicht vorhanden ist. Eine Antiplättchenwirkung organischer Nitrate in vivo bzw. ex vivo wird daher über die Stimulation eines endothelialen, thrombozyteninhibitorischen Faktors erklärt. Hierbei sind Prostazyklin sowie ein bisher unbekannter Endothel-zellfaktor neben einer synergistischen Wirkung organischer Nitrate mit endogenem Prostazyklin in Diskussion. Eine thrombozytenfunktionshemmen-de Wirkung organischer Nitrate könnte in Kombination mit ihren hämody-namischen Effekten auch für die an-tianginöse Wirkung in der Klinik bedeutsam sein, insbesondere zur Verhinderung vasospastischer Zustände bei der instabilen Angina pectoris.

• Literatur

• 1 Abshagen U. Organic nitrates. In: Clinical Pharmacology of Antianginal Drugs. Abs-hagen U. (ed) Berlin, Heidelberg, New York: Springer; 1985: 287-364.
• 2 Ahland B. Zur Wirkung von Glyzeryltrinitrat auf Gefäßtonus, Plättchenfunktion und Arachidonsäuremetabolismus in Gefäßwand und Thrombozyten. Inauguraldissertation, Köln 1987.
• 3 Ahlner J, Andersson R.G.G, Axelsson K.L, Bunnfors I, Wallentin L. Effects of dipyridamol on the glyceryl trinitrate-in-duced inhibition of coronary artery muscle tone and platelet aggregation in relation to cyclic nucleotide metabolism. Acta Pharmacol Toxicol 1985; 57: 88-95.
• 4 Aiken J.W, Gorman R.R, Shebuski R.J. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 1979; 17: 483-94.
• 5 Armstrong P.W, Moffat J.A, Marks G.S. Arterial-venous nitroglycerin gradient during intravenous infusion to man. Circulation 1982; 66: 1273-6.
• 6 Azuma H, Ishikawa M, Sekizaki S. Endo-thelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88: 411-5.
• 7 Baenziger N.L, Dillender M.J, Majerus P.W. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem Biophys Res Comm 1977; 78: 294-301.
• 8 Berenger F.P, Cano J-P, Rolland P.H. Antithrombogenic endothelial cell defense: Basal characteristics in cultured endothelial cells and modulation by short-term and long-term exposure to isosorbide nitrates. Circ Res 1987; 60: 612-20.
• 9 Blajchman M.A, Senyi A.F, Hirsh J, Surya Y, Buchanan M, Mustard J.F. Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest 1979; 63: 1026-35.
• 10 Block H.U, Forster W, Heinroth I. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue-and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A₂ formation. Arzneim Forsch 1982; 32: 189-94.
• 11 Böhme E, Jung R, Mechler J. Guanylate cyclase in human platelets. Methods Enzy-mol 1974; 38: 199-202.
• 12 Böhme E, Grossmann G, Spiess C, Mülsch A. Biochemischer Wirkungsmechanismus von Molsidomin. Med Klin 1985; Sondernummer 1: 12-6.
• 13 Brown B.G, Bolsón E, Peterson R.E, Pierce C.D, Dodge H.T. The mechanism of nitroglycerin action: Stenosis of vasodilation as a major component of the drug response. Circulation 1984; 64: 1091-9.
• 14 Busse R, Pohl U, Bassenge E. Wirkung von Teopranitol auf den Tonus perfundierter Arterien und Venen in vitro. In: Therapie der koronaren Herzkrankheit mit Teopranitol. Bender F, Gerlach E. (eds) Darmstadt: Steinkopff; 1986: 33-41.
• 15 Cairns J.A, Gent M, Singer J. Aspirin, sulfinpyrazone or both in unstable angina. Results of a Canadian Multicenter Trial. New Engl J Med 1985; 313: 1369-75.
• 16 Darius H, Ahland B, Rücker W, Klaus W, Peskar B.A, Schrör K. The effect of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation and eicosanoid formation in vitro – inhibition of 12-HPETE biosynthesis. J Cardiovasc Pharmacol 1984; 6: 115-21.
• 17 Darius H, Weiss P, Schrör K. Stereospeci-fic stimulation of coronary vascular PGI₂ by organic nitrates – studies with the new compound teopranitol (KC-046). Biomed Biochim Acta 1984; 43: 269-72.
• 18 Davi G, Cannizzaro S, Giubilato A, Novo S, Mattina A, Strano A. Enhanced platelet sensitivity to prostacyclin after isosorbide-5-mononitrate in patients with stable angina pectoris. Z Kardiol 1986; 75, Suppl 3: 80-2.
• 19 Davidson M.M.L, Haslam R.J. Roles of cyclic nucleotides in the inhibition of platelet function by nitroprusside and ascor-bate. Thromb Haemost 1981; 46: 149.
• 20 De Caterina R, Gianessi D, Crea F, Chierchia S, Bernini W, Gazzetti P, L’Abbate A. Inhibition of platelet function by injectable isosorbide dinitrate. Am J Cardiol 1984; 53: 1683-7.
• 21 De Caterina R, Dorso C.R, Tack-Goldman K.B.S, Weksler B.B. Nitrates and endothelial prostacyclin production: studies in vitro. Circulation 1985; 71: 176-82.
• 22 De Caterina R, Gianessi D, Bernini W, Mazzone A. Mechanism of the in vivo antiplatelet activity of isosorbide dinitrate. Eur Heart J 1987; Suppl: 11.
• 23 De Rubertis F.R, Craven P.A. Calcium-independent modulation of cyclic GMP and activation of guanylate cyclase by nitrosoamines. Science 1976; 143: 887-9.
• 24 Epstein S.E, Palmeri S.T. Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: Implications regarding therapy. Am J Cardiol 1984; 54: 1245-52.
• 25 Fam W.M, McGregor M. Effect of coronary vasodilator drugs on retrograde flow in areas of chronic myocardial ischemia. Circ Res 1964; 15: 355-65.
• 26 Feelisch M, Noack E.A. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139: 19-30.
• 27 Feelisch M, Noack E.A, Schröder H. Explanation of the discrepancy between the degree of organic nitrate decomposition nitrite formation and guanylate cyclase stimulation. Eur Heart J 1988; (im Druck).
• 28 Feldman R.L, Conti C.R. Relief of myocardial ischemia with nitroglycerin : What is the mechanism?. Circulation 1981; 64: 1098-100.
• 29 Fiedler V.B. Reduction of occlusive coronary artery thrombosis and myocardial ischemia by molsidomine in anesthetized dogs. Canad J Physiol Pharmacol 1982; 60: 1104-11.
• 30 FitzGerald D.J, Roy L, Robertson R.M, FitzGerald G.A. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation 1984; 70: 297-302.
• 31 FitzGerald G.A, Pedersen A.K, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-7.
• 32 Folts J.D, Cromwell Jr E.G, Rowe G.G. Platelet aggregation in partially obstructed coronary vessels and its elimination with aspirin. Circulation 1976; 54: 365-70.
• 33 Fung H.L. Pharmacokinetics of nitroglycerin and long-acting nitrate esters. Am J Med 1983; 74 Suppl. 6B 13-20
• 34 Fung H-L, Sutton S.C, Kamiya A. Blood vessel uptake and metabolism of organic nitrates in the rat. J Pharmacol Exp Ther 1984; 228: 334-41.
• 35 Furlong B, Henderson A.H, Lewis M.J, Smith J.A. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 1987; 90: 687-92.
• 36 Ganz W, Marcus H.S. Failure of intracoro-nary nitroglycerin to alleviate pacing-induced angina. Circulation 1972; 46: 880-9.
• 37 Glusa E, Markwardt F, Stürzebecher J. Effects of sodium nitroprusside and other pentacyanonitrosyl complexes on platelet aggregation. Haemostasis 1974; 3: 249-56.
• 38 Hampton J.R, Harrison M.J.G, Honour A.J, Mitchell J.R.A. Platelet behaviour and drugs used in cardiovascular disease. Cardiovasc Res 1967; 1: 101-7.
• 39 Handin R.I, McDonough M, Lesch M. Elevation of platelet factor four in acute myocardial infarction. J Lab Clin Med 1978; 91: 340-9.
• 40 Haslam R.J, Davidson M.M.L, Fox J.E.B, Lynham J.A. Cyclic nucleotides in platelet function. Thromb Haemost 1978; 40: 232-40.
• 41 Haslam R.J, Davidson M.M.L, Lynham J.A. Functional significance of the effects of sodium nitroprusside (SNP) and prostaglandin E₁ (PGE,) on cyclic nucleotides and protein phosphorylation in human platelets. Fed Proc 1979; 38: 232 (Abstr)
• 42 Horowitz J.D, Antman E.M, Lorell B.H, Barry W.H, Smith T.W. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983; 68: 1247-53.
• 43 Ignarro L.J, Lippton H, Edwards J.C, Baricos W.H, Hyman A.L, Kadowitz P.J, Grutter C.A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide. Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218: 739-49.
• 44 Jakubowski J.A, Stampfer M.J, Vaillan-court R, Faigel D, Deykin D. Low-dose enteric coated aspirin : a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. J Lab Clin Med 1986; 108: 616-26.
• 45 Karrenbrock B.R, Grewe K, Loschke K, Gerzer R. A comparative study of the effects of SIN-1, sodium nitroprusside and nitrates on inhibition of platelet aggregation and activation of soluble guanylate cyclase in human platelets. Path Biol 1987; 35: 251-4.
• 46 König E, Löbel P, Schrör K, Weiss P. Stereochemical relationship of organic nitrates for coronary PGL stimulation, vessel tone and platelet function. Br J Pharmacol 1986; 87: 114P.
• 47 Kukovetz W.R, Holzmann S. Cyclic cGMP as the mediator of molsidomine-induced vasodilatation. Eur J Pharmacol 1986; 122: 103-9.
• 48 Kukovetz W.R, Holzmann S, Wurm A, Pöch G. Evidence for cyclic GMP-medi-ated relaxant effects of nitro compounds in coronary smooth muscle. Naunyn-Schmie-deberg’s Arch Pharmacol 1979; 310: 129-38.
• 49 Levin R.I, Jaffe E.A, Weksler B.B, Tack-Goldman K. Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest 1981; 67: 762-9.
• 50 Levin R.I, Weksler B.B, Jaffe E.A. The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function. Circulation 1982; 66: 1299-307.
• 51 Levine S, Lindenfeld P.J, Ellis J.B, Raymond N.M, Krentz L.S. Increased plasma concentrations of platelet factor 4 in coronary artery disease. Circulation 1981; 64: 626-32.
• 52 Lichtenthal P.R, Rossi E, Louis G, Rehnberg K.A, Wade L.D, Michaelis L.L, Fung H-L, Patrignani P. Dose-related prolongation of the bleeding time by intravenous nitroglycerin. Anesth Analg 1985; 64: 30-3.
• 53 Loscalzo J. N. Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76: 703-8.
• 54 Loscalzo J, Freedman J. Purification and characterization of human platelet gluta-thione-S-transferase. Blood 1986; 67: 1595-9.
• 55 Maclntyre D.E, Bushfield M, Shaw A.M. Regulation of platelet cytosolic free calcium by cyclic nucleotides and protein kinase C. FEBS Lett 1985; 188: 383-8.
• 56 Lucas F.V, Skrinska V.A, Chisolm G.M, Hesse B.L. Stability of prostacyclin in human and rabbit whole blood and plasma. Thromb Res 1986; 43: 379-87.
• 57 Maseri A, L’Abbate A, Baroldi G, Chierchia S, Marzilli M, Ballestra A.M, Severi S, Parodi O, Biagini A, Distante A, Pesóla A. Coronary vasospasm as a possible cause of myocardial infarction. New Engl J Med 1978; 299: 1271-7.
• 58 Maseri A, Severi S, Distante A, Chierchia S, Mimmo R, Ballestra A.M, Pesóla A. Evidence of relief by nitrates of angina pectoris related to coronary artery spasm. In: Nitrate – Wirkungen auf Herz und Kreislauf. Rudolph W, Siegenthaler W. (eds) München: Urban & Schwarzenberg; 1976: 90-3.
• 59 McNiff E.F, Yakobi A, Young-Chang F.M, Golden L.H, Goldfarb A, Fung H.L. Pharmacokinetics of nitroglycerin after intravenous infusion in normal subjects. J Pharm Sci 1981; 70: 1054-8.
• 60 Mehta J, Mehta P. Comparative effects of nitroprusside on platelet aggregation in patients with heart failure. J Cardiovasc Pharmacol 1980; 2: 25-33.
• 61 Mehta J, Mehta P, Roberts A, Faro R, Ostrowski N, Brigmon L. Comparative effects of nitroglycerin and nitroprusside on prostacyclin generation in adult human vessel wall. J Am Coll Cardiol 1983; 2: 625-30.
• 62 Mellion R.T, Ignarro L.J, Myers C.B, Ohlstein E.H, Ballot B.A, Hyman A.L, Kadowitz P.J. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-de-pendent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol 1983; 23: 653-64.
• 63 Mellion B.T, Ignarro L.I, Ohlstein E.H, Pontecorvo E.G, Hyman A.L, Kadowitz P.J. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-55.
• 64 Morcillio E, Reid P.R, Dubin N, Ghod-gaonkar R, Pitt B. Myocardial prostaglandin E release by nitroglycerin and modification by indomethacin. Am J Cardiol 1980; 45: 53-7.
• 65 Mülsch A, Böhme E, Busse R. Stimulation of soluble guanylate cyclase by endothe-lium-derived relaxing factor from cultured endothelial cells. Eur J Pharmacol 1987; 135: 247-50.
• 66 Murray J.J, Fridovich I, Makhoul R.G, Hägen P.O. Stabilization and partial characterization of endothelium-derived relaxing factor from cultured aortic endothelial cells. Biochem Biophys Res Comm 1986; 141: 689-96.
• 67 Nakabayashi S, Uyama O, Nagatsuka K, Uehara A, Wanaka A, Yoneda S, Kimura K, Kamata T. The effect of isosorbide dinitrate and isosorbide 5-mononitrate on prostacyclin (PGI₂) and thromboxane A₂ (TXA₂) generation in rat and human arteries. Res Comm Chem Pathol Pharmacol 1985; 47: 323-32.
• 68 Nakashima S, Tomatsu T, Hattori H, Oka-no Y, Nozawa Y. Inhibitory role of cyclic GMP on secretion, polyphosphoinosite hydrolysis and calcium mobilization in thrombin-stimulated human platelets. Biochem Biophys Res Comm 1986; 135: 1099-104.
• 69 Nishikawa M, Kanamori M, Hidaka H. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent Molsidomine and its metabolites. J Pharmacol Exp Ther 1982; 220: 183-90.
• 70 Noack E. Investigations on structure-activity relationships in organic nitrates. Methods Find Exp Clin Pharmacol 1984; 6: 583-6.
• 71 Noack E, Schröder H, Feelisch M. Continuous determination of nitric oxide formation during non-enzymatic degradation of organic nitrates and its correlation to guanylate cyclase activation. Naunyn-Schmiedeberg’s Arch Pharmacol 1986; Suppl 332: R32
• 72 Ouyang P, Reid P. Ibuprofen inhibition of trinitroglycerin in the isolated perfused cat coronary artery. Circulation 1980; 62:Suppl iti, 256.
• 73 Palmer R.M.J, Ferrige A.G, Moneada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
• 74 Pareti F.I, Carrera D, Mannucci L, Mannucci P.M. Effect on platelet functions of derivatives of cyclic nucleotides. Thromb Haemost 1978; 39: 404-9.
• 75 Parker J.O. Nitrate therapy in stable angina pectoris. New Engl J Med 1987; 316: 1635-42.
• 76 Pascal N. Nitrate – Gemeinsamkeiten und Unterschiede. Med Klinik 1986; 81 Sondernummer 1: 3-69
• 77 Pfleiderer T. Na-nitroprusside, a very potent platelet disaggregating substance. Acta Univ Carol Med 1972; 53: 247-50.
• 78 Philp R.B, Paul M.L. Low-dose aspirin (ASA) renders human platelets more vulnerable to inhibition of aggregation by prostacyclin (PGI₂). Prostaglandins Leu-kotrienes Med 1983; 11: 131-42.
• 79 Pifer D.D, Cagen L.M, McChasney C. Stability of prostaglandin I₂ in human blood. Prostaglandins 1981; 2: 165-75.
• 80 Prescott L.F, Illingworth R.N, Critchley J.A.J.H. et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2: 1097-100.
• 81 Rapoport R.M, Waldmann S.A, Ginsburg R, Molina C.R, Murad F. Effects of glyceryltrinitrate in endothelium-depen-dent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J Cardiovasc Pharmacol 1987; 10: 82-9.
• 82 Rettkowski W, Pönicke K, Block H.U, Gießler C.h, Dunemann A, Zehl U, Förster W. Studies of the influence of nitroglycerin on the synthesis of prostaglandins and thromboxane A₂ and on platelet aggregation. Arzneim Forsch 1982; 32: 194-200.
• 83 Ring T, Knudsen F, Kristensen S.D, Larsen C.E. Nitroglycerin prolongs bleeding time in healthy males. Thromb Res 1983; 29: 553-9.
• 84 Rolland P.H, Berenger F.P, Cano J-P. In vitro evidence of an endothelial cell-dependent antiplatelet activity for isosorbide dinitrate, but not for its 2- and 5-mononitrate metabolites. J Pharmacol Exp Ther 1987; 240: 234-40.
• 85 Rolland P.H, Bory M, Leca F, Sainsous J, Gueydon E, Iuhan I, Serradigmini A, Cano J-P. Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans. Prostaglandins Leukotrienes Med 1984; 16: 333-46.
• 86 Rolland P.H, Sampol J, Lacarelle B, Arnoux D, Leca F, Gueydon E, Cano J-P. Differential inhibitory effects of isosorbide dinitrate and its mononitrate metabolites on platelet aggregation and thromboxane formation. Pharm Res 1985; 17: 87-90.
• 87 Schafer A.I, Alexander R.W, Handin R.I. Inhibition of platelet function by organic nitrate vasodilators. Blood 1980; 55: 649-54.
• 88 Schoepflin G.S, Pickett W, Austen K.F, Goetzl E.J. Elevation of the cyclic GMP concentration in human platelets by sodium ascorbate and 5-hydroxytryptamine. J Cyclic Nucleotide Res 1977; 3: 355-65.
• 89 Schröder H, Noack E. New results in thiol-dependent activation of guanylate cyclase by organic nitrates. Z Kardiol 1986; 75, Suppl 3: 20-24.
• 90 Schröder H, Noack E, Müller R. Evidence for a correlation between nitric oxide formation by cleavage of organic nitrates and activation of guanylate cyclase. J Molec Cell Cardiol 1985; 17: 931-4.
• 91 Schrör K, Ahland B, Darius H, Weiss P. Stimulation of vascular PGI₂ by organic nitrates and its significance for the antianginal effect. Scand J Lab Clin Med 1984; 44, Suppl 173: 33-40.
• 92 Schrör K, Grodzinska L, Darius H. Stimulation of coronary vascular prostacyclin and inhibition of human platelet thromboxane A₂ after low-dose nitroglycerin. Thromb Res 1981; 23: 59-65.
• 93 Schrör K, König E, Ahland B, Weiss P. Stimulation of coronary vascular PGI₂ by organic nitrates. Eur Heart J 1987; (im Druck).
• 94 Schrör K, Weiss P, Darius H. Wirkung von Teopranitol (KC 046) auf Koronargefäßto-nus und Prostazyklinbil d u n g in vitro im Vergleich zu anderen Nitraten. In: Bender F, Gerlach E. (Hrsg) Therapie der Angina pectoris mit Teopranitol. Darmstadt: Steinkopff; 1984: 41-8.
• 95 Schrör K, Weiss P, Löbel P, Darius H, Latta G. Organische Nitrate und Prostaglandine im kardiovaskulären System. Z Kardiol 1986; 75, Suppl 3: 30-4.
• 96 Sinzinger H, Silberbauer K, Feigl W, Wagner O, Winter M, Auerswald W. Prostacyclin activity is diminished in different types of morphologically controlled human atherosclerotic lesions. Thromb Haemost 1979; 42: 803-4.
• 97 Smith J.B, Ingerman C.M, Silver M.J. Platelet prostaglandin production and its implications. Adv Prostaglandin Thromboxane Res 1976; 2: 747-53.
• 98 Sobel M, Salzman E.W, Davies G.C. et al. Circulating platelet products in unstable angina pectoris. Circulation 1981; 63: 300-6.
• 99 Steer M.L, Mclntyre D.E, Levine L, Salzman E.W. Is prostacyclin a physiologically important circulating anti-platelet agent?. Nature 1980; 283: 194-5.
• 100 Takano S, Anzei T, Ogawa J, Suzuki T. Effects of antianginal drugs on platelet aggregation of rabbits. Fukushima J Med Sci 1980; 27: 25-9.
• 101 Tanayama S, Nakai Y, Fujita T, Suzuki Z. Biotransformation of molsidomine (N-eth-oxycarbonyl-3-morpholinosydnonimine), a new antianginal agent, in rats. Xenobiotica 1974; 4: 175-91.
• 102 Tateson J.E, Moneada S, Vane J.R. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13: 389-97.
• 103 Thiemermann C, Smith III E.F, Schrör K. Successful treatment of acute myocardial ischemia with teopranitol, a novel organic nitrate. Eur Heart J 1986; 7: 418-24.
• 104 Torresi J, Horowitz J.D, Dusting G.J. Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine. J Cardiovasc Pharmacol 1985; 7: 777-83.
• 105 Trimarco B, Cuocolo A, van Dorne D. et al. Late phase of nitroglycerin-induced coronary vasodilatation blunted by inhibition of prostaglandin synthesis. Circulation 1985; 71: 840-8.
• 106 Uchida Y, Murao S. Cyclic changes in peripheral blood pressure of partially constricted coronary artery. Jap Coll Angiol 1974; 14: 383.
• 107 Uchida Y, Murao S. Effect of prostaglandin 12 on cyclical reductions of coronary blood flow. Jap Circ J 1979; 43: 645-52.
• 108 van Dusen J, Fischi S. Inhibition of nitroglycerin effect in humans by suppression of prostaglandin E. Am J Cardiol 1978; 47: 390 (Abstr)
• 109 Weber S, Rey E, Pipeau C, Lutfalla G, Richard M-O, Daoud-El-Assaf H, Olive G, Degeorges M. Influence of aspirin on the hemodynamic effects of sublingual nitroglycerin . J Cardiovasc Pharmacol 1983; 5: 874-7.
• 110 Weill D, Maclouf J, Vallantin X, Wautier J.L. Effect of molsidomine treatment on platelet activation. Pathol Biol (Paris) 1987; 35: 219-21.
• 111 Winbury M.M, Hawe B.B, Weiss H.R. Effects of nitroglycerin and dipyridamole on epicardial and endocardial oxygen tension. Further evidence for redistribution of myocardial blood flow. J Pharmacol Exp Ther 1971; 176: 184-99.
• 112 Winniford M.D, Jackson J, Malloy C.R, Rehr R.B, Campbell W.B, Hillis D. Does indomethacin attenuate the coronary vasodilator effect of nitroglycerin?. J Am Coll Cardiol 1984; 4: 1114-7.